Quick Answer
Damora Therapeutics, Inc. reported Cash and Equivalents of $257.62 million for fiscal year 2025.
Damora Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $257.62M | +1717.5% |
| 2024 | $14.18M | -34.0% |
| 2023 | $21.46M | -34.5% |
| 2022 | $32.79M | -47.6% |
| 2021 | $62.56M | -61.8% |
| 2020 | $163.58M | +1348.4% |
| 2019 | $11.29M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $7.61M | -61.3% | -25.5% |
| June 30, 2025 | $10.21M | -55.3% | -14.5% |
| March 31, 2025 | $11.94M | -43.4% | -15.8% |
| December 31, 2024 | $14.18M | -34.0% | -28.0% |
| September 30, 2024 | $19.68M | -14.7% | -13.9% |
| June 30, 2024 | $22.86M | -0.4% | +8.4% |
| March 31, 2024 | $21.09M | -15.9% | -1.7% |
| December 31, 2023 | $21.46M | -34.5% | -7.0% |
- Damora Therapeutics, Inc. showed an increase of +1717.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Damora Therapeutics, Inc.’s cash and equivalents has grown by 2181.1% (from $11.29 million to $257.62 million).
- The most recent figure is from Damora Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: